Skip to content
MarketScale
‹ Back to IndustriesSciences

How Is the Conversation around Space Sustainability Evolving?

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.   Space to Grow closed out its first season with a wrap-up episode with hosts Chris Blackerby and Charity Weeden from Astroscale. They looked back on past…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · Orbital EnvironmentsSpace ImpactSpace PolicySpace Sustainability
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

Space to Grow closed out its first season with a wrap-up episode with hosts Chris Blackerby and Charity Weeden from Astroscale.

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

Space to Grow closed out its first season with a wrap-up episode with hosts Chris Blackerby and Charity Weeden from Astroscale. They looked back on past conversations regarding space sustainability, policy, technology, and more. Then shared what they hope to bring to the show in its second season.

“The best part has been the guests we’ve had and the diversity of those voices,” Weeden said. Blackerby echoed this sentiment, highlighting the nine space experts who were on the show.

“The space community recognizes the importance, but most people outside of it don’t know how space affects them because it’s hard to grasp. Our speakers explained how orbital environments and space impact society.” – Chris Blackerby

Weeden noted a central theme in their messages on achieving sustainability. “It’s time to change our culture and how we view space to make it more sustainable.”

Blackerby also remarked about how their conversations have created awareness of the impact on society. “The space community recognizes the importance, but most people outside of it don’t know how space affects them because it’s hard to grasp. Our speakers explained how orbital environments and space impact society.”

While they covered many topics, Weeden said, “We could’ve been more technology focused and explaining how the technology works. Space sustainability is a multi-disciplinary issue.”

Blackerby agreed they should prioritize technical topics. He also wants to dig in more on the fundraising, customer development, investments, and business side of space. “There are more stories about the growth of companies, big and small, and how they form and grow to tell.”

Ultimately, the resounding emphasis of the show is promoting the responsible use of space and moving to a “leave no trace” culture.

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

CB
Chris Blackerby

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby